Johnson & Johnson (JNJ)
3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.
Amid recession worries and tumbling markets; President Trump's tariffs are still helping the U.S. economy achieve key wins. Many huge corporations have announced plans to invest billions in U.S. manufacturing.
Dividend Kings Face-Off: Johnson & Johnson (JNJ) Vs. Procter & Gamble (PG)
If you are someone who thinks investments should generate regular income, it is important to watch out for dividend stocks.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Dividend Kings Down Today: Why Johnson & Johnson (JNJ), Coca-Cola (KO) and Procter & Gamble (PG) Are Sliding
Some analysts expect Procter & Gamble to cut its forecast thanks to uncertainty over spending with global trade tensions.
Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
2 Recession-Proof Stocks to Buy With a Better Credit Rating Than the U.S. Government
In 2011, following the difficulty caused by the Great Recession, S&P Global Ratings (formerly Standard & Poor's) downgraded the long-term credit outlook of the United States from its highest designation of AAA to AA+, citing budgetary issues. Fitch once again downgraded U.S. credit in 2023 and Moody's recently suggested it's contemplating a similar move.
Johnson & Johnson Pivots Its AI Strategy
The company is making a shift to focus on only the highest-value GenAI use cases and shut down pilots that were redundant or underdelivering.
Here's How You Should Play JNJ Stock After Q1 Earnings Beat
Those who own JNJ stock may stay invested for some time to see how the company achieves growth in 2025 amid the various challenges.
The Relief Rally Is Over: 4 Incredible Dividend Monarchs Are Our Safest Ideas Now
While it was fun while it lasted, as we have discussed before, inevitably, after vicious sell-offs like the one we saw from the market peak in February, which pushed the S&P 500 and the Nasdaq quickly into a brief bear market 20% decline territory, there is the potential for stunning bear market rallies.
This Super-Safe High-Yield Stock Just Extended Its Dividend Growth Streak to 63 Years in a Row
Johnson & Johnson (JNJ 0.22%) continues to treat its investors like royalty. The healthcare behemoth recently gave them another raise, increasing its dividend payment by 4.8%.
ETFs in Focus Post JNJ's Q1 Earnings Beat, Dividend Hike
Johnson & Johnson reports strong first-quarter 2025 results, raises revenue guidance and boosts its quarterly dividends.
Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?
On the one hand, the company beat on the top and bottom lines and offered better-than-expected guidance. On the other hand, JNJ acknowledged the likelihood of a $400 million tariff hit on the company's medical device business that will impact business in the short term.
